These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 28386752

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Interaction between irbesartan, peroxisome proliferator-activated receptor (PPAR-γ), and adiponectin in the regulation of blood pressure and renal function in spontaneously hypertensive rats.
    Afzal S, Sattar MA, Johns EJ, Abdulla MH, Akhtar S, Hashmi F, Abdullah NA.
    J Physiol Biochem; 2016 Dec; 72(4):593-604. PubMed ID: 27405250
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Twenty-four-hour ambulatory blood pressure evaluation of antihypertensive agents.
    Zanchetti A.
    J Hypertens Suppl; 1997 Dec; 15(7):S21-5. PubMed ID: 9532517
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques.
    Davi H, Tronquet C, Miscoria G, Perrier L, DuPont P, Caix J, Simiand J, Berger Y.
    Drug Metab Dispos; 2000 Jan; 28(1):79-88. PubMed ID: 10611144
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients.
    Chen G, Jiang S, Mao G, Zhang S, Hong X, Tang G, Li Z, Liu X, Zhang Y, Xing H, Wang B, Yu Y, Xu X.
    Methods Find Exp Clin Pharmacol; 2006 Jan; 28(1):19-24. PubMed ID: 16541193
    [Abstract] [Full Text] [Related]

  • 35. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH, Lee H, Paik SH, Lee JH, Yoo BW, Kim JH, Tan HK, Kim SL.
    Am J Cardiovasc Drugs; 2011 Oct 01; 11(5):335-46. PubMed ID: 21910510
    [Abstract] [Full Text] [Related]

  • 36. Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension.
    Neutel JM, Franklin SS, Bhaumik A, Lapuerta P, Oparil S.
    Clin Exp Hypertens; 2009 Oct 01; 31(7):572-84. PubMed ID: 19886855
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.
    Strutz F, Bramlage P, Paar WD.
    Curr Med Res Opin; 2005 Sep 01; 21(9):1433-40. PubMed ID: 16197662
    [Abstract] [Full Text] [Related]

  • 39. Clinical overview of irbesartan: expanding the therapeutic window in hypertension.
    Man in't Veld AJ.
    J Hypertens Suppl; 1997 Dec 01; 15(7):S27-33. PubMed ID: 9532518
    [Abstract] [Full Text] [Related]

  • 40. Individual and joint association of alpha1A-adrenergic receptor Arg347Cys polymorphism and plasma irbesartan concentration with blood pressure therapeutic response in Chinese hypertensive subjects.
    Jiang S, Mao G, Zhang S, Hong X, Tang G, Li Z, Liu X, Zhang Y, Wang B, Xu X, Wang X.
    Clin Pharmacol Ther; 2005 Sep 01; 78(3):239-48. PubMed ID: 16153395
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.